Genetron Holdings Net Income 2020-2021 | GTH

Genetron Holdings net income from 2020 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Genetron Holdings Annual Net Income
(Millions of US $)
2020 $-470
2019 $-95
Genetron Holdings Quarterly Net Income
(Millions of US $)
2021-06-30 $-14
2021-03-31 $-17
2020-12-31 $-46
2020-09-30 $-7
2020-06-30 $-401
2020-03-31 $-16
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.219B $0.065B
Genetron Holdings Limited provides precision oncology platform principally in China. It specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company's product and service portfolio cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. Genetron Holdings Limited is based in BEIJING, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.216B 8.54
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.812B 20.00
Biohaven Pharmaceutical Holding (BHVN) United States $8.815B 0.00
Emergent Biosolutions (EBS) United States $2.763B 6.66
Arcus Biosciences (RCUS) United States $2.321B 0.00
Myovant Sciences (MYOV) United Kingdom $1.993B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.769B 0.00
Zymeworks (ZYME) Canada $1.152B 0.00
Ambrx Biopharma (AMAM) United States $0.431B 0.00
SQZ Biotechnologies (SQZ) United States $0.346B 0.00
Enzo Biochem (ENZ) United States $0.188B 18.43